Lupin Gets US FDA Nod For Nagpur Facility With Zero Observations

Lupin on Thursday announced that it has received an establishment inspection report from the US Food and Drug Administration for its injectables facility in Nagpur with zero observations.

The report pertains to the US FDA inspection carried out in its site, which manufactures drug-device combination products, during June 10-13 2024, the company said in an exchange filing